Subscribe
istock-519319356_charlieaja
charlieAJA / iStockphoto.com
19 July 2017Big Pharma

Pharma organisations underline Brexit concerns in letter to negotiators

The Association of the British Pharmaceutical Industry (ABPI) and seven other UK and European life sciences bodies have jointly written to the UK and EU Brexit negotiators.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AstraZeneca seeks three-year Brexit transition period
5 October 2017   The chairman of pharmaceutical company AstraZeneca wants a transition period of three years following the UK’s exit from the EU.
Big Pharma
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16 November 2018   While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
AstraZeneca seeks three-year Brexit transition period
5 October 2017   The chairman of pharmaceutical company AstraZeneca wants a transition period of three years following the UK’s exit from the EU.
Big Pharma
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16 November 2018   While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.

More on this story

Big Pharma
AstraZeneca seeks three-year Brexit transition period
5 October 2017   The chairman of pharmaceutical company AstraZeneca wants a transition period of three years following the UK’s exit from the EU.
Big Pharma
Brexit draft deal: a welcome step but more certainty needed, say lawyers
16 November 2018   While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers